Status:
COMPLETED
Staccato Loxapine Pulmonary Safety in Patients With Asthma
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.
Eligibility Criteria
Inclusion
- History of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator FEV1 ≥60% of predicted value.
Exclusion
- History of COPD, or any other acute or chronic pulmonary disease
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00890175
Start Date
May 1 2009
End Date
August 1 2009
Last Update
March 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergy and Asthma Medical Group & Research Center, A.P.C.
San Diego, California, United States, 92123